TREATMENT OF ESSENTIAL TREMOR, USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUORETHOXY)PYRIDINE-2-YL)ETHYL)ACETAMIDE Russian patent published in 2022 - IPC A61K31/4412 A61K9/14 A61K9/16 A61K9/48 A61P25/08 A61P25/14 

FIELD: medicine; pharmacology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to pharmacology, and discloses a dosage form for oral use for the treatment of essential tremor, containing Cav3 blocker, where Cav3 blocker is CX-8998, or its pharmaceutically acceptable salt, where the oral dosage form contains a component with controlled release, containing the specified Cav3 blocker, and where the oral dosage form contains a component with instant release, containing the specified Cav3 blocker; where the specified oral dosage form, when administered to a human once a day, is effective for maintenance of maximal concentration in plasma (C_max) of the specified Cav3 blocker, divided by a medium concentration of the specified Cav3 blocker in plasma 24 hours after administration (from 1.0 to 4.0). A method for the treatment of a human suffering from a motor disorder is also disclosed.

EFFECT: maximization of daily efficiency of CX-8998, limitation of C_max of related side effects, and limitation of sleep disorder at night time (and potentially, hormonal levels), while reducing a frequency of taking a drug, necessary for a therapeutic effect.

10 cl, 74 dwg, 53 tbl, 40 ex